Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30pm, Friday, 02'nd Jul 2021
RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
09:00am, Friday, 18'th Jun 2021
RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board
G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
07:00am, Wednesday, 16'th Jun 2021
RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey
G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela
09:33am, Monday, 14'th Jun 2021
G1 Therapeutics Inc (NASDAQ: GTHX) has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC).
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Jun 2021
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercis
- Combination of Rintodestrant and Palbociclib was Very Well Tolerated with No Reported Discontinuations due to Treatment-Emergent Adverse Events (TEAEs) -
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today presented results from analyses evaluating the immu
G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
05:01pm, Wednesday, 19'th May 2021
RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced upcoming data presentations at the American S
- A Cost-Benefit Model of Administration of COSELATM (trilaciclib) Prior to Chemotherapy Estimates Measurable Per-Patient Cost Savings -
PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors PRESERVE 4 Will Evalu
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 07'th May 2021
RESEARCH TRIANGLE PARK, N.C., May 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisa
GTHX Stock: 10.22% Increase (From $19.77 To $21.79) Pre-Market Explanation
06:51am, Thursday, 06'th May 2021
The stock price of G1 Therapeutics Inc (NASDAQ: GTHX) increased 10.22% (from $19.77 to $21.79) pre-market. This is why it happened.
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call Transcript
11:09pm, Wednesday, 05'th May 2021
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call Transcript
G1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue Estimates
07:10pm, Wednesday, 05'th May 2021
G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 40.37% and 3711.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aileron Therapeutics: Solving Chemotherapy's Toxicity
09:54pm, Friday, 30'th Apr 2021
Aileron Therapeutics: Solving Chemotherapy's Toxicity
